Medscape June 13, 2022
The odds of a person with type 1 diabetes achieving target A1c levels and avoiding severe hypoglycemia increase with greater degrees of automation in the technology they’re using, new real-world data show.
Most notably, the likelihood of experiencing a severe hypoglycemic episode in the prior year was more than double for those taking multiple daily injections (MDI) of insulin without use of a continuous glucose monitor (CGM) compared with those using hybrid closed-loop automated insulin delivery, also known as artificial pancreas systems.
“It seems that with each incremental increase in technology you see a decrease in A1c. CGM seems to add that extra jump,” said Kellee M. Miller, PhD, MPH, who presented the findings from the T1D Exchange registry at...
Today's Sponsors
Today's Sponsor